Continuous positive airway pressure (CPAP) is the standard treatment for moderate-to-severe obstructive sleep apnoea (OSA). However, adherence to CPAP is limited and non-CPAP therapies are frequently explored. Oral appliance (OA) therapy is currently widely used for the treatment of snoring, mild, moderate and severe OSA. The most commonly used and studied OA consists of a maxillary and mandibular splint which hold the lower jaw forward during sleep. The efficacy of OA is inferior to CPAP; however, the effectiveness as measured by sleepiness, quality of life, endothelial function and blood pressure is similar likely due to higher acceptance and subjective adherence. Upper airway stimulation augments neural drive by unilaterally stimulating the hypoglossal nerve. The Stimulation Therapy for Apnea Reduction (STAR) study enrolled 126 patients and demonstrated a 68% reduction in OSA severity. A high upfront cost and variable response are the main limitations. Oropharyngeal exercises consist of a set of isometric and isotonic exercises involving the tongue, soft palate and lateral pharyngeal wall. The collective reported trials (n = 120) showed that oropharyngeal exercises can ameliorate OSA and snoring (~30-40%). Nasal EPAP devices consist of disposable one-way resister valve. A systematic review (n = 345) showed that nasal EPAP reduced OSA severity by 53%. The Winx device consists of a mouthpiece placed inside the oral cavity that is connected by tubing to a console that generates negative pressure. Winx may provide successful therapy for~30-40% of OSA patients. In conclusion, several non-CPAP therapies to treat OSA are currently available.
INTRODUCTION
Nasal continuous positive airway pressure (CPAP) remains the standard of care for patients with moderateto-severe obstructive sleep apnoea (OSA). CPAP is able to completely abolish OSA by acting as a pneumatic splint that keeps the upper airway open during sleep. 1 However, there are several reasons to support the development of new alternative treatments for OSA. Two large epidemiological studies in Brazil 2 and Switzerland 3 as well as the follow-up of the Wisconsin cohort 4 demonstrated that a large proportion of the adult population (10-49.7%, depending on the age group and diagnostic criteria) have some degree of OSA. The reasons for prevalence that is higher than estimated over 20 years ago (OSA plus symptoms of excessive daytime sleepiness: 2% and 4% in females and males, respectively) 5 include the obesity epidemic, the incorporation of new technologies to detect hypopnoeas (nasal cannula) and the understanding that a large proportion of OSA patients do not complain of typical symptoms such as excessive daytime sleepiness. Most OSA participants diagnosed in epidemiological studies do not present with severe OSA, do not have typical symptoms and therefore are not the ideal candidates for CPAP. Currently, our personal observation is that it is much more common to see patients in sleep clinics with mild forms of OSA that are less likely to benefit from CPAP than it was 20 years ago. Moreover, even the patients with severe OSA who qualify for CPAP frequently face problems of acceptance and poor adherence. 6 The rate of CPAP adherence remains persistently low, with an average CPAP use of 4.4 h per night in reported trials. 7 No clinically significant improvement in CPAP adherence has been reported in recent years despite new CPAP and mask technology. 7 For example, a recent large multicentre study failed to show that the treatment of moderate-to-severe OSA with CPAP decreased mortality in patients with established cardiovascular disease (Sleep Apnea Cardiovascular Endpoints (SAVE) study). One of the main limitations of the study was that the mean duration of adherence to CPAP therapy of 3.3 h per night highlighting the difficulty related to CPAP adherence. 8 Behavioural approaches such as avoiding alcohol and sedatives near bedtime, avoiding sleep in the supine position and maximizing nasal patency may be helpful in specific groups of patients. [9] [10] [11] Intensive lifestyle intervention or bariatric surgery resulting in significant weight loss is effective in reducing OSA severity. 12, 13 Such approaches have been proposed as possible treatments for mild-to-moderate OSA either in isolation or in combination with other therapies. Weight loss is effective at reducing OSA severity and improving OSA symptoms, but rarely leads to a cure of OSA. Traditional surgical interventions directed at shortening and stiffening the palate (i.e. palatal procedures) or upper airway reconstruction in the case of maxillomandibular reconstruction have unfortunately limited high quality evidence and are associated with significant morbidity.
14 None of these options consistently result in the successful elimination of OSA. In addition, there are no clear predictors, as to which patients will respond most favourably to which specific treatment. One possibility is to customize treatment by better characterizing the dominant mechanism leading to OSA. Phenotyping is based on the concept that there are four primary traits that contribute to OSA: (i) Upper airway anatomy that to some extent contributes to upper airway collapse in all patients; (ii) The upper airway response of pharyngeal dilator muscles that can compensate for anatomical deficiency; (iii) Arousal threshold; and (iv) Loop gain. The latter two traits are the measures of respiratory instability. Unstable respiratory control, characterized by a low arousal threshold and a high loop gain, contributes to cycle between sleeping hypopnoea and waking hyperpnoea. 15 One interesting approach is to target multiple pathways by the use of combination therapy as is the case in the treatment of other complex diseases such as hypertension. For instance, one recent study reported that combination therapy directed at stabilizing respiratory control by raising the arousal threshold (3 mg eszopiclone) and lowering the loop gain (40% oxygen) resulted in a 50% average reduction of the apnoea-hypopnoea index (AHI) among patients with severe OSA. Combination therapy was considered effective only in the patients (9/20) whose anatomy was not severely compromised. 16 The purpose of this review is not to thoroughly cover all non CPAP therapies, but focus on selective treatments either because they are well established or because of promising results. We therefore direct the reader interested in the effect weight loss, 12, 13 positional therapy 10 and upper airway surgery 14 on OSA to recent reviews.
ORAL APPLIANCE
Oral appliances (OA) are dental splints used to keep the mandible in an advanced position, preventing upper airway collapse during sleep. After CPAP, OA is the second most common therapy used to treat OSA. OA are currently widely used for the treatment of snoring and mild, moderate or severe OSA, both as primary therapy and as an alternative for patients who are unwilling or unable to tolerate CPAP. 17 OA are a simple, reversible, quiet and cost-effective therapy for selected patients with OSA. The majority of OA are designed to maintain the mandible and/or tongue in a protruded position, thereby preventing upper airway obstruction during sleep. While CPAP and OA therapies reduce upper airway collapse during sleep, they differ in efficacy, cost and side effects. An important consideration in the treatment with OA therapy is the type of OA used. There are a variety of studies that show how the decrease in AHI is dependent upon the amount of mandibular advancement. [18] [19] [20] [21] [22] Adjustable OA devices are titrated until optimum symptom relief and achieve a significantly greater reduction in the AHI for patients with a baseline AHI >10 events/h. 23 Custom-made, titratable appliances have been demonstrated to be more effective than the 'boil and bite' types. 24 One study from England has shown that simple non-adjustable OA achieved clinically important improvements in mild-tomoderate OSA and are cost-effective. 25 Although side effects related to the use of OA are usually classified as mild and transient, these side effects along with insufficient reduction of snoring are the main reasons for discontinuing treatment. 26 Initial side effects can include excessive salivation, dry mouth, mouth or tooth discomfort, morning occlusal changes, discomfort in the gums, muscle tenderness and jaw stiffness. Custom-made OA can be adjusted to reduce pressure on the teeth and gums. A decrease in the mandibular advancement can also improve muscle tenderness. In the majority of the cases, these side effects resolve with time. In addition, temporomandibular joint discomfort is often a concern for patients and professionals involved in OA therapy. There is evidence of a limited risk of developing pain or functional impairment of the long-term temporomandibular complex with OA treatment. 27 Bite changes are commonly reported by patients after a period of 1-2 years of continuing OA use. [28] [29] [30] [31] [32] [33] Interestingly, different appliance designs such as Herbst, Mobloc, Klearway (Great Lakes Orthodontics, Buffalo, USA), Somnomed (SomnoMed Ltd, Australia) and TAP (Airway Management Inc, Dallas, Texas, USA) have reported that the amount of occlusion change was not related to the type of appliance used but rather related to the duration of therapy. 34 Craniofacial changes related to OA do occur and are mainly related to dental alveolar movements. Of note, the patient's perception does not typically correlate with objective measurements and occlusal changes often go unnoticed. 33 New occlusal contacts result from new occlusal equilibrium over time. 35 Discussions between dentist, sleep physician and patients are important to understand these bite changes. The changes are generally described as a forward movement of the lower teeth and a small backward movement of the upper teeth. In general terms, patients should expect a decrease in the overjet by average of 2.5 mm after 10 years of OA wear. 36 Perceptions of side effects and the benefits of OA have to be assessed in a patient-specific evaluation and despite the development of irreversible long-term occlusal changes, OA therapy should be considered as a lifelong treatment for patients with OSA.
OA therapy has been frequently restricted to mild cases of OSA (Table 1) . However, there is evidence of a positive correlation in the amount of AHI reduction with OA and the baseline AHI, 37 in other words, the higher the baseline AHI the greater the decrease in OSA severity with OA. Although quite encouraging, the rate of achieving an AHI <5 events/h or <10 is smaller as the disease severity increases. Based on the average of success rates of two recent studies, 38 the OA success rate in reducing the AHI to <5 events/h was 55% for mild, 45% for moderate and 35% for severe OSA. If a partial success (50% improvement in AHI) is also considered as beneficial, another 10% of success for mild, 25% for moderate and 30% for severe cases is observed. OA therapy often results in a suboptimal treatment with residual apnoeas and hypopnoeas on the range of 15-20 events/h. 38 Despite the inferiority of efficacy when compared with CPAP, OA is highly comparable to the effectiveness of CPAP therapy due to the inferior adherence to CPAP as compared with OA. Several randomized controlled studies have compared CPAP with OA, and demonstrated that the two therapies had similar effectiveness in symptoms such as sleepiness, quality of life and biomarkers of cardiovascular disease such as blood pressure, 39, 40 endothelial function, 41, 42 and microvascular reactivity. 43 In a recent meta-analysis, despite residual respiratory events with OA treatment, OA achieved similar effects in the reduction of blood pressure when compared with CPAP. 39, 44 The population worldwide is getting heavier and obesity is an important contributing factor to the pathogenesis of OSA. It has been suggested that an increase in weight is correlated with a decrease in OA efficacy. 45 Further studies on OA efficacy on patients with BMI > 35 are needed.
OA should be considered not only an alternative to CPAP but rather a potentially complementary treatment modality to further improve treatment outcomes. The combination of OA and CPAP to be used on alternative days has been reported as a successful approach. 46 Almeida et al. found that patients who were compliant with CPAP (>4 h/night) had their sleepiness further improved once they had the option to use an OA when CPAP was not being worn. Patients did describe a smaller burden of this therapy, having an option for a day off CPAP, and also described less pressure on teeth, having a day off OA. Combination therapies may help to improve adherence with a decrease of a specific treatment side effect or burden.
In conclusion, OA are a simple, reversible, quiet and cost-effective therapy for many patients with snoring, mild, moderate and severe OSA. The current literature shows strong evidence that OA have similar long-term effectiveness compared with CPAP and improve sleep, reduce obstructive apnoeas and hypopnoeas, reduce blood pressure and improve daytime sleepiness and quality of life.
UPPER AIRWAY STIMULATION
Unlike CPAP that 'pneumatically splints' the airway open and OA that mechanically repositions the mandible resulting in opening the airway and possibly upregulating upper airway muscle tone, upper airway stimulation (UAS) augments neural drive by unilaterally stimulating the hypoglossal nerve. The only device that is currently approved by Food and Drug Administration (FDA) in the USA (Inspire Medical Systems, Inc., MN, USA) provides phasic stimulation of the hypoglossal nerve via a cuff electrode connected to an implanted impulse generator that incorporates an effort sensor placed between the intercostal muscles ( Fig. 1) . Because the tongue is a hydrostat, the stimulation sequence can be programmed to have the tongue protrude forward with stimulation as opposed to the right or left. The UAS system is activated via a patient programmer that is utilized only during the sleep period. While the primary mechanism of UAS is forward movement of the tongue, mechanical coupling with the soft palate results in airway enlargement in both the retrolingual and retropalatal airways. 48 The UAS system can be implanted as an outpatient. The surgery is performed by otolaryngologists primarily because of the familiarity of identifying the hypoglossal nerve for placement of the stimulation cuff. Nerve integrity monitoring is performed intraoperatively to ensure the optimal site of the placement of the cuff electrode to activate protrusor muscles (primarily genioglossus and geniohyoid) and avoid activation of retrusor muscles (primarily hyoglossus and styloglossus). 49 Perioperative pain can be easily managed with non-narcotic analgesics (acetaminophen and or non-steroidal antiinflammatory medications). 50 Device activation occurs after 1 month post-operation, so that the stimulation and sensing leads can become secure with healing of the surgical fields. The therapeutic voltage that is delivered is determined during an attended sleep study. Much like CPAP titrations, the voltage is incrementally increased to the desired effect-resolution of sleep-disordered breathing. In general, the additional stimulation parameters, rate and pulse width, are held constant at 33 Hz and 90 ms, respectively.
The Stimulation Therapy for Apnea Reduction (STAR) trial provided definitive data regarding safety and efficacy of the Inspire Medical Systems device. 47 The STAR trial was a 12-month prospective multicentre cohort study with a randomized therapy withdrawal arm in participants with moderate-to-severe OSA who had not accepted or adhered to CPAP therapy. The coprimary outcome measures were the AHI and the 4% oxygen desaturation index (ODI). Participants with a BMI of >32 kg/m 2 , concentric collapse observed on drug-induced sedation endoscopy (DISE) at the level of the palate 51, 52 and positional OSA (non-supine AHI >10 events/h) were excluded. The participants enrolled (n = 126) were primarily middle-aged males (83%) with a BMI = 28.4 AE 2.6 kg/m 2 . DISE excluded~7.0% of the participants who were initially screened (54/598). The retention rate for the cohort was 98% at 12 months. UAS resulted in a robust improvement in all the primary and secondary outcome measures. From baseline to 12 months, there was a 68% reduction in the AHI (29 to 9 events/h) and a 70% reduction in the ODI (25.4 to 7.4 events/h). Similar improvements were seen in the Epworth Sleepiness Scale (ESS) and the Functional Outcomes of Sleep Questionnaire (FOSQ). The arousal index decreased from median value of 28.9 (interquartile range (IQR): 20.5-40.8) to 14.8 (IQR: 10.3-24.8). There was no change in the BMI or blood pressure from baseline to 12 months. Serious adverse events included one participant who required a device revision and there was one participant death unrelated to the trial (homicide). Other non-serious adverse events included~25% of participants who experienced transient pain related to the procedure and~33% of the participants who experienced transient tongue discomfort/abrasion related to the device. 2 The randomized controlled therapy withdrawal portion of the STAR trial included the first 46 consecutive responders (defined as an AHI of <20% and >50% reduction in the AHI from baseline). Therapy was suspended for 1 week in the withdrawal group and maintained in the control group. At 1 week with therapy off (n = 23), there was an increase back towards baseline compared with the continued therapy group (n = 23). The STAR trial cohort has been serially assessed at 18, 24 and 36 months. [3] [4] [5] 53 Key findings of these reports have indicated that improvements in the primary and secondary outcome measures have been stable. No significant change in the stimulating voltage was required and somewhat surprisingly the BMI for the cohort remained unchanged. The principal challenges regarding implementation of UAS relate primarily to two issues. The first is that not all participants respond to this therapy. In the STAR trial, 43 of 126 (34%) participants did not respond. The second is that the upfront cost of UAS is $US30 000 (Table 1) . When modelling for costeffectiveness of UAS over a lifetime, the discounted incremental cost-effectiveness ratio (ICER) is~$ US40 000. 6 Similar modelling has determined that the ICER for CPAP is~$US15 000 with the cost distributed over the lifetime of treatment (replacement of machines and disposables) as opposed to the upfront costs for UAS (primarily for surgery). Cost-effectiveness is obtained when the ICER is less than two to three times the per capita income for a given population. In the case of the USA, the per capita annual income is~$US54 000. 7 With these assumptions, UAS at a lifetime cost of~$US40 000 would be considered cost-effective. 54 The Inspire device is currently the only FDA approved UAS system. Other devices are currently under development and undergoing preclinical and pre-FDA clinical trials. One such device is the Imthera UAS system (ImThera Medical, San Diego, USA). Phase II clinical trials have demonstrated a treatment effect at 3 and 12 months. 55 This system, as opposed to the Inspire UAS system, employs a slightly different technology. No sensing lead is incorporated into the device. The stimulation paradigm involves primarily 'tonic' as opposed to 'phasic' stimulation. One potential advantage is that the hypoglossal cuff electrode can be placed more proximally. The results of the ongoing Phase III trial will establish whether the safety and effectiveness is similar to the Inspire Device (NCT02263859 at Clinicaltrials.gov).
A transcutaneous submental electrical stimulation (TCSES) system has been developed. 56 Proof of concept reports that involve laboratory assessment alone have been published. The primary barrier to this technology is the need to deliver higher voltages transcutaneously to achieve a treatment effect. These higher voltages have the potential to disrupt sleep. Further research is needed to clarify the role of TCSES in the treatment armamentarium for OSA.
Over 1000 Inspire UAS systems have been implanted worldwide since obtaining FDA approval in April 2014. A few single-centre case series relating to the Inspire UAS system have been published. Outcomes related to the AHI are favourable and consistent with the STAR trial data. 8, 9 Enrolment has begun for a patient registry involving the Inspire Device. In addition to the impact on the AHI and patient-reported outcomes, objective adherence data will be collected (NCT02413970 at Clinicaltrials.gov). The adherence reports will have a look and feel similar to the data presented in PAP adherence reports.
In conclusion, UAS is an additional tool for managing properly selected patients with moderate-to-severe OSA at risk for cardiac and metabolic complications and who cannot tolerate PAP therapy. Before proceeding to UAS, it is prudent to assess the possibility of OA as a treatment option. Identifying OSA endotypes that would benefit from UAS is paramount. Understanding the UAS responder endotypes will likely be related to more precise hypoglossal nerve mapping, understanding the limits of augmenting the neural response and how UAS impacts anatomy. Anatomical assessments will likely involve imaging (either endoscopic or radiological) and/or polysomnography (i.e. Pcrit (critical closing pressure)). UAS is not an option for morbidly obese patients. Examining the role of complementary treatments in incomplete responders with targeted surgery, OA, weight loss or medications needs to be explored. Finally, the value of alternative stimulation strategies using 'tonic' versus 'phasic' or TCSES needs to be understood.
OROPHARYNGEAL EXERCISES
Because the dilator muscles of the upper airway play a critical role in maintaining an open airway during sleep, 57 several recent studies have investigated the effects of oropharyngeal exercises on OSA severity. Guimarães et al. randomized 31 patients with moderate OSA either to a sham therapy (n = 15) or to a set of oropharyngeal exercises derived from speech therapy (n = 16), consisting of isometric and isotonic exercises involving the tongue, soft palate and lateral pharyngeal wall. 58 Three months of exercise training reduced OSA severity by 39%, evaluated by the AHI and lowest oxygen saturation determined by polysomnography. One recent systematic review and meta-analysis found nine adult studies (120 patients) that evaluated the impact of oropharyngeal exercises (also quoted as myofunctional therapy) on OSA. 59 The majority of the adult patients had moderate OSA, and the group data showed an average of 50% reduction in AHI. The major limitation was that only two studies (43 patients) were randomized controlled trials (RCT). 58, 60 Two additional RCT must also be discussed. One study in 25 patients with moderate OSA showed that 4 months of training of the upper airways by didgeridoo playing reduced daytime sleepiness and OSA severity. 61 The upper airway training provided by didgeridoo playing is unique since it requires circular breathing, a technique that enables the wind instrumentalist to maintain a sound for long periods of time by inhaling through the nose while maintaining airflow through the instrument, using the cheeks as bellows. More recently, Ieto et al. performed another RCT in 39 patients referred because of snoring. The authors showed that 3 months of oropharyngeal exercises reduced objectively measured snoring frequency by 36% and overnight power of snoring by 59%. 62 The four RCT published so far are consistent and show beneficial effects of oropharyngeal exercises on OSA severity and symptoms. Complete remission of OSA was rarely observed and several questions remain unanswered. It is not clear how exercises performed while awake can influence the behaviour of upper airway during sleep. One possibility is that the set of exercises promotes remodelling of the upper airway; however, this concept remains speculative. Another challenge is that the number of exercises and muscles targeted are not homogeneous between studies. The oropharyngeal exercises are based on an integrative approach and therefore do not allow determining the effects of each specific exercise on the overall result. More importantly, the exercises must be performed by the patient with frequency (two or three times a day) and this may limit the clinical applicability (Table 1) . Therefore, how well patients adhere to oropharyngeal exercises in 'real-world' clinical practice is unknown.
NASAL EPAP
Nasal EPAP devices consist of disposable one-way resister valves that are placed over the nostrils with an adhesive tape. These valves operate by utilizing the patient's own breathing to create a positive end-expiratory pressure with minimal inspiratory resistance. This high end-expiratory pressure leads to upper airway dilation with subsequent tracheal traction and increased lung volumes during exhalation, thereby making the upper airway more resistant to narrowing/closure during ensuing inspiration. 63, 64 In contrast to CPAP, patients using nasal EPAP may collapse the upper airway during inspiration. It is unclear how EPAP works. One study suggested that the Provent device (Provent Sleep Therapy, LLC, Manchester, USA) leads to substantial hypoventilation during both wakefulness and sleep that could stabilize breathing by increasing respiratory drive to both pump and upper airway dilator muscles. 63 This mechanism of stabilizing breathing may also help to explain the observation that EPAP improved night-time oxygen desaturation triggered by high altitude. 65 Several studies have evaluated the efficacy of Provent to treat OSA. [66] [67] [68] A recent systematic review showed that 345 patients evaluated showed a 53% mean relative reduction in the AHI with the use of nasal EPAP. 69 The Provent device can successfully treat~35-50% of the patients with mild-tomoderate OSA. One limitation is that there are no clear predictors of who will benefit from Provent. 70 Another caveat is that adherence with the device is difficult to measure, and long-term adherence is difficult to evaluate. The long-term cost is also high as it is designed as a single nightly use device (Table 1) .
WINX
The Winx device (ApniCure, Redwood, USA) consists of a mouthpiece that is placed inside the oral cavity that connects by tubing to a console that generates negative pressure (50 cm H 2 O). The concept is that when negative pressure is applied in the mouth, the uvula and soft palate are pulled forward against the base of the tongue and the pharyngeal airway lumen is increased. Based on the limited data, obtained from 63 patients with all severities of OSA, the Winx device can provide successful therapy for~30-40% of OSA patients. 71 One potential limitation is that the system is not very different from a CPAP machine, and the longterm acceptance/adherence to the device remains to be established (Table 1) .
CONCLUSIONS
Several well-established and emerging new therapies beyond CPAP are currently available to treat OSA. OA is the best first treatment option for patients with mild OSA. There is also evidence that this therapy can be effective in moderate-to-severe OSA. In contrast to CPAP, OA may frequently not achieve a complete abolition of OSA. On the other hand, the inferiority may be compensated by a higher adherence to OA. The effectiveness in treating OSA in clinical practice with OA may be similar to CPAP. There is currently one UAS approved by FDA that is a promising treatment alternative to CPAP and OA for patients with moderate-tosevere OSA. Oropharyngeal exercises, nasal EPAP and Winx are based on different principles, and the majority of studies have shown at least some beneficial effects on OSA severity. Because the response to all these treatments is heterogeneous, the major challenge in this area is to find predictors of response. Another promising approach is to use combination therapies to treat OSA. 
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